Profile data is unavailable for this security.
About the company
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
- Revenue in USD (TTM)0.00
- Net income in USD-64.84m
- Incorporated2018
- Employees32.00
- LocationBicara Therapeutics Inc116 Huntington Avenue, Suite 703BOSTON 02116United StatesUSA
- Phone+1 (617) 468-4219
- Fax+1 (302) 655-5049
- Websitehttps://www.bicara.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc | 10.01m | -345.20m | 972.50m | 294.00 | -- | 1.16 | -- | 97.19 | -2.61 | -2.61 | 0.076 | 5.03 | 0.0109 | -- | -- | 30,978.33 | -37.58 | -28.55 | -39.69 | -29.54 | -- | -- | -3,449.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Septerna Inc | 840.00 | -10.27k | 974.88m | 68.00 | -- | -- | -- | 1,160,577.00 | -0.0003 | -0.0003 | 0.00002 | 0.0037 | -- | -- | -- | 12.35 | -- | -- | -- | -- | -- | -- | -792.86 | -- | -- | -- | 0.00 | -- | -- | -- | 102.06 | -- | -- | -- |
| Nuvation Bio Inc | 2.16m | -532.28m | 992.87m | 203.00 | -- | 1.97 | -- | 459.24 | -2.17 | -2.17 | 0.009 | 1.50 | 0.0036 | -- | 0.5936 | 42,392.16 | -88.53 | -16.27 | -94.44 | -16.65 | -32.38 | -- | -24,619.84 | -- | -- | -- | 0.0165 | -- | -- | -- | 27.25 | -- | -- | -- |
| Lenz Therapeutics Inc | 0.00 | -72.31m | 999.38m | 6.00 | -- | 4.87 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.02bn | 37.00 | -- | 176.15 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.07bn | 267.00 | -- | 6.73 | -- | 4.23 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Arrivent Biopharma Inc | 0.00 | -74.89m | 1.07bn | 40.00 | -- | 3.60 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Bicara Therapeutics Inc | 0.00 | -64.84m | 1.08bn | 32.00 | -- | -- | -- | -- | -1.25 | -1.25 | 0.00 | 3.72 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Pharvaris NV | 0.00 | -120.52m | 1.08bn | 82.00 | -- | 3.08 | -- | -- | -2.52 | -2.52 | 0.00 | 6.51 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| MiMedx Group Inc | 342.81m | 90.79m | 1.10bn | 895.00 | 15.06 | 6.06 | 11.03 | 3.20 | 0.4961 | 0.4601 | 2.00 | 1.23 | 1.58 | 2.63 | 6.65 | 383,022.30 | 44.93 | -4.14 | 56.00 | -5.90 | 83.37 | 83.61 | 28.37 | -2.70 | 3.53 | 22.35 | 0.0951 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| Cogent Biosciences Inc | 0.00 | -242.30m | 1.14bn | 164.00 | -- | 5.63 | -- | -- | -2.48 | -2.48 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -65.53 | -49.53 | -74.36 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Aurinia Pharmaceuticals Inc | 220.36m | -22.55m | 1.18bn | 300.00 | -- | 3.05 | -- | 5.37 | -0.1582 | -0.1582 | 1.53 | 2.71 | 0.3991 | 0.7854 | 5.92 | 734,536.70 | -4.08 | -25.97 | -4.74 | -28.24 | 87.25 | -- | -10.23 | -137.64 | 5.11 | -- | 0.1725 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Zymeworks Inc | 62.20m | -113.67m | 1.19bn | 294.00 | -- | 3.29 | -- | 19.14 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Cassava Sciences Inc | 0.00 | -17.66m | 1.21bn | 29.00 | -- | 7.25 | -- | -- | -0.3772 | -0.3772 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -8.91 | -30.74 | -10.98 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Bicara Therapeutics Inc's reporting currency: US Dollar USD
22.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 16 Sep 2024 | 6.96m | 12.79% |
| Invus Public Equities Advisors LLCas of 16 Sep 2024 | 3.04m | 5.59% |
| Deerfield Management Co. LPas of 17 Sep 2024 | 1.80m | 3.30% |
| First Turn Management LLCas of 30 Sep 2024 | 562.39k | 1.03% |
| TD Asset Management, Inc.as of 30 Sep 2024 | 102.42k | 0.19% |
| New York State Common Retirement Fundas of 30 Sep 2024 | 17.23k | 0.03% |
| Legato Capital Management LLCas of 30 Sep 2024 | 14.18k | 0.03% |
| JPMorgan Chase Bank, NA (Investment Management)as of 30 Sep 2024 | 730.00 | 0.00% |
| Kessler Investment Group LLCas of 30 Sep 2024 | 200.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
